This Article
Right arrow Full Text (PDF)
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowReprints and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sumner, D. R.
Right arrow Articles by Galante, J. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sumner, D. R.
Right arrow Articles by Galante, J. O.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Technorati  
What's this?

The Journal of Bone and Joint Surgery, Vol 77, Issue 8 1135-1147, Copyright © 1995 by Journal of Bone and Joint Surgery, Inc


JOURNAL CONTENTS

Enhancement of bone ingrowth by transforming growth factor-beta

DR Sumner, TM Turner, AF Purchio, WR Gombotz, RM Urban and JO Galante
Department of Orthopedic Surgery, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA.

Enhancement of bone ingrowth with transforming growth factor-beta was evaluated in a canine model. Ten dogs had bilateral implantation of a titanium-fiber-metal-coated rod in the proximal part of the humerus. A three-millimeter gap between the outer surface of the porous coating and the surrounding cancellous bone was created to impair bone ingrowth. All of the implants were plasma-flame-sprayed with hydroxyapatite and tricalcium phosphate. In each animal, one implant was also treated with recombinant transforming growth factor-beta 1 while the other implant, which was not so treated, served as a paired control. Two doses of transforming growth factor-beta 1 were used: 335 micrograms in five animals and 120 micrograms in the other five. At four weeks, the amount of bone ingrowth in the implants that had been treated with 120 micrograms of transforming growth factor-beta 1 was threefold higher than that in the paired controls (p = 0.009), but with the numbers available there was no significant increase in bone ingrowth with the higher dose. The amount of new-bone formation in the three-millimeter gaps adjacent to the treated implants was twice that in the gaps of the paired controls, regardless of the dose. The differences between the treated and control implants with regard to the architecture of the new bone in the gap indicate that the mechanism of action of transforming growth factor-beta 1 may include both proliferation of osteoprogenitor cells and production of matrix by committed osteoblasts. Compared with the findings in a previous study in which this canine model was used, the data from the present investigation indicate that enhancement of bone ingrowth in implants that have been treated with a combination of a hydroxyapatite-tricalcium phosphate coating and transforming growth factor-beta 1 may exceed that obtainable with grafting of the gap with autogenous cancellous bone.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
JBJSHome page
P. L. Hays, S. Kawamura, X.-H. Deng, E. Dagher, K. Mithoefer, L. Ying, and S. A. Rodeo
The Role of Macrophages in Early Healing of a Tendon Graft in a Bone Tunnel
J. Bone Joint Surg. Am., March 1, 2008; 90(3): 565 - 579.
[Abstract] [Full Text] [PDF]


Home page
JBJSHome page
J. Goldhahn, B. Mitlak, P. Aspenberg, J. A. Kanis, R. Rizzoli, J.-Y. Reginster, and the GREES (Group for the Respect of Ethics and Exc
Critical Issues in Translational and Clinical Research for the Study of New Technologies to Enhance Bone Repair
J. Bone Joint Surg. Am., February 1, 2008; 90(Supplement_1): 43 - 47.
[Abstract] [Full Text] [PDF]


Home page
JBJSHome page
D.R. Sumner, T.M. Turner, R.M. Urban, A.S. Virdi, and N. Inoue
Additive Enhancement of Implant Fixation Following Combined Treatment with rhTGF-beta2 and rhBMP-2 in a Canine Model
J. Bone Joint Surg. Am., April 1, 2006; 88(4): 806 - 817.
[Abstract] [Full Text] [PDF]


Home page
J Bone Joint Surg BrHome page
J. F. Quinlan, R. W. G. Watson, G. Kelly, P. M. Kelly, J. M. O'Byrne, and J. M. Fitzpatrick
Transforming growth factor-beta (TGF-{beta}) in acute injuries of the spinal cord
J Bone Joint Surg Br, March 1, 2006; 88-B(3): 406 - 410.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
K. Janssens, P. ten Dijke, S. Janssens, and W. Van Hul
Transforming Growth Factor-{beta}1 to the Bone
Endocr. Rev., October 1, 2005; 26(6): 743 - 774.
[Abstract] [Full Text] [PDF]


Home page
JBJSHome page
H. Cheng, W. Jiang, F. M. Phillips, R. C. Haydon, Y. Peng, L. Zhou, H. H. Luu, N. An, B. Breyer, P. Vanichakarn, et al.
Osteogenic Activity of the Fourteen Types of Human Bone Morphogenetic Proteins (BMPs)
J. Bone Joint Surg. Am., August 1, 2003; 85(8): 1544 - 1552.
[Abstract] [Full Text] [PDF]


Home page
JBJSHome page
J. R. Lieberman, A. Daluiski, and T. A. Einhorn
The Role of Growth Factors in the Repair of Bone : Biology and Clinical Applications
J. Bone Joint Surg. Am., June 1, 2002; 84(6): 1032 - 1044.
[Full Text] [PDF]


Home page
J Am Acad Orthop SurgHome page
R. Illgen II and H. E. Rubash
The Optimal Fixation of the Cementless Acetabular Component in Primary Total Hip Arthroplasty
J. Am. Acad. Ortho. Surg., January 1, 2002; 10(1): 43 - 56.
[Abstract] [Full Text] [PDF]


Home page
Am J Sports MedHome page
S. A. Rodeo, K. Suzuki, X.-h. Deng, J. Wozney, and R. F. Warren
Use of Recombinant Human Bone Morphogenetic Protein-2 to Enhance Tendon Healing in a Bone Tunnel
Am. J. Sports Med., July 1, 1999; 27(4): 476 - 488.
[Abstract] [Full Text] [PDF]